Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Recruiting 3Withdrawn 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Gynecologic 3Gastrointestinal 3Head & Neck 2Breast 2Genitourinary 1Dermatologic 1

Conditions

Colorectal Neoplasms 48Squamous Cell Carcinoma of Head and Neck 19Carcinoma, Non-Small-Cell Lung 15Neoplasms 11Head and Neck Neoplasms 9Neoplasm Metastasis 8Lung Neoplasms 8Pancreatic Neoplasms 7Colonic Neoplasms 7Carcinoma, Squamous Cell 7Solid Tumors 5Rectal Neoplasms 4Ovarian Neoplasms 3Mouth Neoplasms 3Laryngeal Neoplasms 3Hypopharyngeal Neoplasms 3Gastrointestinal Neoplasms 3Endometrial Neoplasms 3Colorectal Cancer Metastatic 3Carcinoma 3Breast Neoplasms 3Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Recurrence 2Oropharyngeal Neoplasms 2Melanoma 2Locally Recurrent Rectal Cancer 2Carcinoma, Pancreatic Ductal 2Advanced Solid Tumor 2Uterine Cervical Neoplasms 1

Interventions

pembrolizumab 25Paclitaxel 20Carboplatin 17Bevacizumab 12Specimen Handling 10Letrozole 10abemaciclib 7dostarlimab 6Taxes 6Fulvestrant 6Megestrol Acetate 5Medroxyprogesterone Acetate 5Magnetic Resonance Spectroscopy 5Drug Therapy 5Doxorubicin 5Cisplatin 5Blood Specimen Collection 5Biopsy 5olaparib 4lenvatinib 4atezolizumab 4Radiotherapy 4Progestins 4Observation 4Nivolumab 4Immunoglobulin G 4Gemcitabine 4trastuzumab deruxtecan 3palbociclib 3X-Rays 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Endometrial Neoplasms × Cetuximab × Clear all
NCT07216105 2026-04-07

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Recruiting
113 enrolled
BreastGastrointestinalGynecologicHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04956640 2025-09-25

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Eli Lilly and Company

Phase 1/2 Recruiting
540 enrolled
GastrointestinalGynecologicThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡